Modified Malonate Derivatives HDAC Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hydroxamic acid derivatives, while effective as histone deacetylase inhibitors for treating cancer and other diseases, have limitations in potency and bioavailability, necessitating the development of new compounds with improved properties.
Innovation Solution
The development of modified malonate derivatives that inhibit histone deacetylase, inducing terminal differentiation and apoptosis in neoplastic cells, thereby inhibiting cell proliferation, and are suitable for treating cancer, autoimmune, allergic, and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxamic acid derivatives are used as histone deacetylase inhibitors, then cancer treatment efficacy is achieved, but potency and bioavailability are limited
Solution Approach 1:
The patent modifies the chemical structure of hydroxamic acid derivatives by changing parameters such as the hydroxamic acid group positioning, molecular weight, and functional group substitutions. These parameter changes result in compounds with improved potency and bioavailability while maintaining HDAC inhibition efficacy for cancer treatment
Solution Approach 2:
The invention creates composite molecular structures combining hydroxamic acid moieties with specific functional groups and scaffolds. These composite structures exhibit enhanced pharmacological properties including improved potency and bioavailability compared to simple hydroxamic acid derivatives
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified malonate derivatives show enhanced activity as histone deacetylase inhibitors, effectively inducing terminal differentiation and apoptosis in neoplastic cells, offering improved therapeutic options for cancer and other TRX-mediated diseases with potentially better bioavailability and efficacy.
Implementation Method 1
compounds having a hydroxamic acid moiety have been shown to inhibit histone deacetylases (HDACs), based at least in part on the zinc binding property of the hydroxamic acid group
Implementation Method 2
the zinc binding property of the hydroxamic acid group
Data Source
AI summary
The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the modified malonate derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the modified malonate derivatives in vivo.